Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/ULTIMOVACS-ASA-59297686/news/Ultimovacs-Announces-Completed-Enrollment-in-FOCUS-Phase-II-Clinical-Trial-of-UV1-in-Head-and-Neck-C-44505041/?utm_source=whatsapp&utm_medium=social&utm_campaign=share